Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ACADEMIA
Generic Shortage Response Evolves into Wakayama’s 1st Regional Formulary
Healthcare stakeholders in Tanabe and Nishimuro in Wakayama Prefecture have developed the western Japan prefecture’s first regional formulary, covering five drug classes commonly used for lifestyle-related diseases. The initiative grew out of local efforts to cope with persistent generic drug…
To read the full story
Related Article
- Regional Formularies Gain Ground, Raising Stakes for Drug Makers, Wholesalers
September 15, 2026
- Regional Formularies Seen Driving Shift to Quality, Industry Consolidation: Society Head
April 27, 2026
- Chuikyo Issues FY2026 Fee Revision Recommendation, Creates New Premiums for Generics and Biosimilars
February 16, 2026
- MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
- MHLW Floats Prefectural Bodies for Regional Formularies, LLP Copay Hike Gains Traction: LDP-Ishin Talks
November 27, 2025
- Japan Society Poised to Set Out Criteria to Standardize Regional Formularies, Eyes August Release
July 31, 2025
ACADEMIA
- HPV Expert Backs Routine Shots for Males, Urges Broader Assessment
October 7, 2026
- Bosutinib Set to Enter PIII for ALS in Japan in 2027
October 6, 2026
- Japan Atherosclerosis Society Proposes 3-Tier Lp(a) Risk Framework
September 16, 2026
- Clinical Value of Lp(a) Unchanged despite Pelacarsen PIII Miss: KOL
September 16, 2026
- Yanagisawa Wins Lasker Award for Unlocking Orexin’s Role in Sleep
September 10, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…